Polymyalgia Rheumatica clinical trials

Explore recruiting polymyalgia rheumatica clinical trials.

Recruiting polymyalgia rheumatica studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Polymyalgia Rheumatica trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

68Ga-FAPI-46 PET for Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Leflunomide in PMR; A multicenter randomized placebo controlled treatment study of Leflunomide in polymyalgia rheumatica

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia Rheumatica

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)

Denmark, Italy, France, Germany, Netherlands, Hungary +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in relapsing PolyMyalgia Rheumatica

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Polymyalgia Rheumatica trials by city

Polymyalgia Rheumatica in Toronto Polymyalgia Rheumatica in Vancouver Polymyalgia Rheumatica in Montreal Polymyalgia Rheumatica in Calgary Polymyalgia Rheumatica in Edmonton Polymyalgia Rheumatica in Ottawa Polymyalgia Rheumatica in Winnipeg Polymyalgia Rheumatica in Quebec City Polymyalgia Rheumatica in Hamilton Polymyalgia Rheumatica in Kitchener Polymyalgia Rheumatica in London Polymyalgia Rheumatica in Halifax Polymyalgia Rheumatica in New York Polymyalgia Rheumatica in Los Angeles Polymyalgia Rheumatica in Chicago Polymyalgia Rheumatica in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease